
Ironwood Pharmaceuticals' future hinges on apraglutide amid generic threats to Linzess by 2029.
Ironwood Pharmaceuticals is rated Buy mainly due to its drug apraglutide, as its current cash flow from Linzess faces pressure from upcoming generic competition expected by 2029 and Medicare price cuts. Linzess revenues are largely committed to debt ...





